FDA Reminder: De Novos, HDEs Provide Cheaper, Faster Way To Market
This article was originally published in The Gray Sheet
Manufacturers are selling themselves short by not using the de novo and Humanitarian Device Exemption (HDE) premarket processes more often, FDA's Don St. Pierre maintains
You may also be interested in...
Organizations like BARDA, CEPI and others are looking to partner with industry to rapidly test, manufacture, package and deploy vaccines and therapeutics, identifying areas they want to work together during BIO’s recent summit.
The economic stress on payers caused by the pandemic will cause a setback in the development of payment approaches for regenerative therapy, Blue Cross Blue Shield executive warns.
An interim final rule posted by the CMS this week widens further a series of telehealth exemptions and lab specimen collection payment provisions it has previously issued to help providers during the COVID-19 pandemic.